In our opinion, these central components include strengthening pathological services (eg, hormone receptor testing in breast cancer, subclassification in non-Hodgkin lymphoma, and determining Gleason score in prostate cancer), ensuring availability of radiation, and training surgeons to perform appropriate procedures. The gene discussed is NR4A1; the disease is prostate carcinoma.